RESUMEN
Germinal centers (GCs) that form in mucosal sites are exposed to gut-derived factors that have the potential to influence homeostasis independent of antigen receptor-driven selective processes. The G-protein Gα13 confines B cells to the GC and limits the development of GC-derived lymphoma. We discovered that Gα13-deficiency fuels the GC reaction via increased mTORC1 signaling and Myc protein expression specifically in the mesenteric lymph node (mLN). The competitive advantage of Gα13-deficient GC B cells (GCBs) in mLN was not dependent on T cell help or gut microbiota. Instead, Gα13-deficient GCBs were selectively dependent on dietary nutrients likely due to greater access to gut lymphatics. Specifically, we found that diet-derived glutamine supported proliferation and Myc expression in Gα13-deficient GCBs in the mLN. Thus, GC confinement limits the effects of dietary glutamine on GC dynamics in mucosal tissues. Gα13 pathway mutations coopt these processes to promote the gut tropism of aggressive lymphoma.
Asunto(s)
Linfocitos B , Proliferación Celular , Subunidades alfa de la Proteína de Unión al GTP G12-G13 , Centro Germinal , Diana Mecanicista del Complejo 1 de la Rapamicina , Ratones Noqueados , Centro Germinal/inmunología , Centro Germinal/metabolismo , Animales , Ratones , Linfocitos B/inmunología , Linfocitos B/metabolismo , Subunidades alfa de la Proteína de Unión al GTP G12-G13/metabolismo , Subunidades alfa de la Proteína de Unión al GTP G12-G13/genética , Diana Mecanicista del Complejo 1 de la Rapamicina/metabolismo , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/inmunología , Nutrientes/metabolismo , Transducción de Señal , Glutamina/metabolismo , Ratones Endogámicos C57BL , Proteínas Proto-Oncogénicas c-myc/metabolismo , Proteínas Proto-Oncogénicas c-myc/genética , Mucosa Intestinal/metabolismo , Mucosa Intestinal/inmunología , Membrana Mucosa/metabolismo , Membrana Mucosa/inmunologíaRESUMEN
Phenyl boronic acids are valuable for medical diagnostics and biochemistry studies due to their ability to readily bind with carbohydrates in water. Incorporated in carbohydrates are 1,2-diols, which react with boronic acids through a reversible covalent condensation pathway. A wide variety of boronic acids have been employed for diol binding with differing substitution of the phenyl ring, with the goals of simplifying their synthesis and altering their thermodynamics of complexation. One method for monitoring their pKa's and binding is 11B NMR spectroscopy. Herein, we report a comprehensive study employing 11B NMR spectroscopy to determine the pKa of the most commonly used phenyl boronic acids and their binding with catechol or d,l-hydrobenzoin as prototypical diols. The chemical shift of the boronic acid transforming into the boronate ester was monitored at pHs ranging from 2 to 10. With each boronic acid, the results confirm (1) the necessity to use pHs above their pKa's to induce complexation, (2) that the pKa's change in the presence of diols, and (3) that 11B NMR spectroscopy is a particularly convenient tool for monitoring these interconnected acidity and binding phenomena.
Asunto(s)
Alcoholes , Ácidos Borónicos , Ácidos Borónicos/química , Alcoholes/química , Espectroscopía de Resonancia Magnética , CarbohidratosRESUMEN
PURPOSE OF REVIEW: Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon complication of acute pulmonary embolism (PE), in which the red, platelet-rich thrombus does not resolve but forms into an organized yellow, fibrotic scar-like obstruction in the pulmonary vasculature. Here we review the pathobiology of CTEPH. RECENT FINDINGS: Our current knowledge has predominantly been informed by studies of human samples and animal models that are inherently limited in their ability to recapitulate all aspects of the disease. These studies have identified alterations in platelet biology and inflammation in the formation of a scar-like thrombus that comprised endothelial cells, myofibroblasts, and immune cells, along with a small vessel pulmonary arterial hypertension-like vasculopathy. The development of CTEPH-specific therapies is currently hindered by a limited knowledge of its pathobiology. The development of new CTEPH medical therapies will require new insights into its pathobiology that bridge the gap from bench to bedside.